The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration

International Ophthalmology

Volumn 35, Issue 4, 2015, Pages 473-480

  Parlak, Melih ^a   Oner, F Hakan ^b   Saatci, A Osman ^b  

^a KLINIKUM KONSTANZ   (Germany)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Age related macular degeneration; Neuroprotection; Ranibizumab; Vascular endothelial growth factor

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; RETINAL NERVE FIBER LAYER THICKNESS; WET MACULAR DEGENERATION; CROSS-SECTIONAL STUDY; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; NERVE FIBER; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINA GANGLION CELL; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; NERVE FIBERS; RANIBIZUMAB; RETINAL GANGLION CELLS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84962626325     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-014-9972-2     Document Type: Article

References (22)

1. Eye Diseases Prevalence Research Group (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122: 477-485.
2. Bressler NM, Bressler SB, Fine SL (1988) Age-related macular degeneration. Surv Ophthalmol 32: 375-413.
3. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379: 1728-1738.
4. Tolentino M (2011) Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 56: 95-113.
5. Breen CE (2007) VEGF in biological control. J Cell Biochem 102: 1358-1367.
6. Nishijima K, Ng YS, Zhong L et al (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171: 53-67.
7. Zhang SH, Yi Q (2009) Effect of VEGF-B on neuroprotection in mouse retinal ganglion cells. Zhonghua Yan Ke Za Zhi 45: 38-42.
8. Saatci AO, Oner FH, Arikan G (2011) Immediate intraocular pressure rise after intravitreal injection of ranibizumab and two doses of triamcinolone acetonide. Int J Ophthalmol 11: 402-405.
9. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J (2009) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye 23: 181-185.
10. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P (2009) Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 18: 658-661.
11. Bakri SJ, McCannelCA, EdwardsAO, MoshfeghiDM(2008) Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 246: 955-958.
12. Kahook MY, Kimura AE, Wong L, Ammar DA, Maycotte MA, Mandava N (2009) Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 40: 293-295.
13. Kilic U, Kilic E, Jaerve A (2006) Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci 26: 12439-12446.
14. Brar VS, Sharma RK, Murthy RK, Chalam KV (2010) Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells. Mol Vis 16: 1848-1853.
15. Seth RK (2009) Assessment of optic nerve cup-to-disc ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents. Retina 29: 956-959.
16. Horsley BM, Mandava N, Maycotte AM (2010) Retinal nerve fiber layer thickness in patients receiving chronic antivascular endothelial growth factor therapy. Am J Ophthalmol 150: 558-561.
17. Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F et al (2012) Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci 53: 6214-6218.
18. Girkin CA, McGwin G Jr, Sinai MJ et al (2011) Variation in optic nerve and macular structure with age and race with spectral-domain optical coherence tomography. Ophthalmology 118: 2403-2408.
19. Bendschneider D, Tornow RP, Horn FK et al (2010) Retinal nerve fiber layer thickness in normals measured by spectral domain OCT. J Glaucoma 19: 475-482.
20. Kim EJ, Hong S, Kim CY, Lee ES, Seong GJ (2011) Attenuated age-related thinning of peripapillary retinal nerve fiber layer in long eyes. Korean J Ophthalmol 25: 248-251.
21. Rouvas A, Liarakos VS, Theodossiadis P (2009) The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration. Ophthalmologica 223: 383-389.
22. Gamulescu MA, Helmig H (2010) Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J Ocul Pharmacol Ther 26: 213-216.